Olivia Newton-John's Long, Open Journey with Breast Cancer

Thirty years, in public

Olivia Newton-John was first diagnosed with breast cancer in 1992, and she said she learned of it the same weekend her father died of cancer. She spoke about it for the next three decades.

NBC News reported that the treatment she described included a partial mastectomy, chemotherapy, and breast reconstruction. By 2020 she was facing stage 4 metastatic breast cancer, her third bout with the disease since 1992. She told NBC's TODAY show that year: "Cancer can engulf your mind and engulf your being. And I try not to live my life with that in my mind all the time."

In 2015 she opened the Olivia Newton-John Cancer Wellness and Research Centre in Australia. She died on August 8, 2022, at 73, at her home in Southern California. Her husband, John Easterling, announced her death, writing that she "has been a symbol of triumphs and hope for over 30 years sharing her journey with breast cancer."

Those are the facts she and her family put on the record. What follows is the disease itself.

What breast cancer is

NCI defines it simply. Breast cancer starts in the breast, in one or both, when breast cells grow without control and form a tumor that may spread elsewhere.

Most cancers start in glandular tissue, either in the milk ducts, called ductal cancer, or in the lobules that make milk, called lobular cancer. Most breast cancers are ductal.

Two other terms matter early on. Carcinoma in situ means the abnormal cells are still inside a duct or lobule and have not moved into surrounding tissue. Invasive cancer has pushed into the surrounding breast, and can reach lymph nodes or distant organs. NCI notes that most breast cancers are invasive.

Less common forms start elsewhere. Phyllodes tumors arise in supporting tissue, Paget disease starts at the nipple, and inflammatory breast cancer occurs when cancer cells block lymph vessels in the skin.

Breast cancer mostly affects women aged 45 and older, and SEER puts the median age at diagnosis at 64. Anyone with breasts can develop it, and it is rare in children and in men.

The changes to notice

NCI stresses that early breast cancer often causes no symptoms at all, which is the entire argument for screening. When changes do appear, NCI lists these:

• A lump in or near the breast, or under the arm.
• A thick or firm area in or near the breast or under the arm.
• A change in the size or shape of a breast.
• Fluid or discharge from the nipple that is not breast milk.
• A nipple that has changed shape, changed the direction it points, or flattened.
• Skin that is scaly, swollen, red, or darkened on the breast, nipple, or areola.
• Itching or tingling in the nipple or areola.
• General swelling of the breast, with no lump present.
• A rash, or dimpling and puckering of the skin.

One point deserves emphasis because it is widely misunderstood. NCI states that breast cancer does not usually cause pain. Breast soreness is far more often caused by cysts, hormonal changes before a period, or certain medicines. Absence of pain is not reassurance, and persistent pain still deserves a visit.

When to get checked

Make an appointment for any of the following, rather than watching it for another cycle:

• Any new lump or firm area in a breast or armpit that is still there after one menstrual cycle, or after two to three weeks if you no longer menstruate.
• Any nipple discharge that is not breast milk, and especially discharge from one side or containing blood.
• A nipple that has newly inverted or changed direction.
• Skin dimpling, puckering, or an orange-peel texture.
• Redness or swelling of one breast that does not settle with antibiotics, which can signal inflammatory breast cancer.
• Breast pain that persists beyond a few weeks.

Symptoms that suggest spread need prompt assessment too. NCI lists back or bone pain, fractures, shortness of breath, a constant dry cough, abdominal pain or swelling, jaundice, severe headaches, seizures, and vision changes among the signs of advanced or metastatic disease.

Screening, and the current recommendation

The US Preventive Services Task Force recommends biennial screening mammography, meaning every two years, for women aged 40 to 74. That is a grade B recommendation.

For women 75 and older, the Task Force concludes that the current evidence is insufficient to weigh benefits against harms. It reaches the same conclusion about adding ultrasound or MRI for women found to have dense breasts on an otherwise negative mammogram.

The Task Force also names an inequity plainly. Black women are more likely to be diagnosed beyond stage 1, more likely to have triple-negative tumors, which lack estrogen receptors, progesterone receptors, and HER2, and roughly 40 percent more likely to die of breast cancer than White women.

Staging, and the questions that shape treatment

Breast cancer is staged twice. Clinical prognostic stage is assigned first, from history, examination, imaging, and biopsy. Pathological prognostic stage is assigned after surgery, using what the laboratory finds in the removed tissue and lymph nodes.

Both produce a number from 0 to IV, and both combine three things: TNM status, meaning tumor size, lymph node involvement, and distant spread; tumor grade, meaning how abnormal the cells look; and biomarker status.

That last item drives treatment more than anything else. The tumor is tested for estrogen and progesterone receptors and for HER2 protein levels. Hormone receptor positive cancers can be treated with hormone therapy, HER2-positive cancers with targeted drugs aimed at that protein, and triple-negative cancers with chemotherapy and, in some cases, immunotherapy. Multigene tests may also be used to help stage and to judge whether chemotherapy is likely to help.

What the numbers show

The American Cancer Society projects about 321,910 new cases of female breast cancer in the United States in 2026, which is 15.2 percent of all new cancer diagnoses, and about 42,140 deaths; SEER reprints those estimates. It is the fourth leading cause of cancer death in the country.

Five-year relative survival across all stages is 91.9 percent for women diagnosed between 2016 and 2022. Relative survival compares people with the cancer to people of the same age and sex without it, which is why the figure for localized disease reaches 100 percent.

By stage, five-year relative survival is 100 percent for localized disease, 87.5 percent for regional spread, and 33.8 percent when the cancer has reached distant organs. Two-thirds of cases, 64 percent, are localized when found. Six percent are distant.

These are population figures covering hundreds of thousands of women with different tumor types, ages, and treatments. They give useful context and nothing more. They do not describe any individual, and they did not describe Olivia Newton-John.

Sources

• https://www.cancer.gov/types/breast/what-is-breast-cancer
• https://www.cancer.gov/types/breast/symptoms
• https://www.cancer.gov/types/breast/stages
• https://seer.cancer.gov/statfacts/html/breast.html
• https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
• https://www.nbcnews.com/news/obituaries/olivia-newton-john-battled-breast-cancer-30-years-rcna42113